Voclosporin - Aurinia Pharmaceuticals

Drug Profile

Voclosporin - Aurinia Pharmaceuticals

Alternative Names: trans-ISA 247; trans-R 1524; ISA(TX)247; ISA-247; ISAtx 247; ISATx247; Orelvo; R-1524; Voclera

Latest Information Update: 02 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isotechnika
  • Developer Atrium Medical Corporation; Aurinia Pharmaceuticals; Isotechnika; Paladin Labs
  • Class Antipsoriatics; Ciclosporins; Eye disorder therapies; Immunotherapies; Skin disorder therapies
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Lupus nephritis
  • Phase I Nephrotic syndrome
  • No development reported Renal transplant rejection
  • Discontinued Coronary artery restenosis; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 27 Oct 2017 Phase-I clinical trials in Nephrotic syndrome (unspecified route) (Aurinia Pharmaceuticals pipeline, October 2017)
  • 20 Oct 2017 Aurinia Pharmaceuticals announces intention to submit rolling NDA for Lupus nephritis in the second half of 2018
  • 20 Oct 2017 Aurinia Pharmaceuticals plans a phase II proof-of-concept trial for Focal-segmental-glomerulosclerosis and Lipoid nephrosis (Minimal change disease) in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top